ArticleESMO open2025

Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 ≥50.

A De Giglio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.